Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference118 articles.
1. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival;Turesson;Eur J Haematol,2018
2. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide;Delforge;Haematologica,2015
3. Health-related quality-of-life results from the open-label, randomized, Phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma;Stewart;J Clin Oncol,2016
4. Analysis of real-world data on overall survival in multiple myeloma patients with >/=3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD;Usmani;Oncologist,2016
5. Multiple myeloma: patient outcomes in real-world practice;Yong;Br J Haematol,2016
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide;Expert Review of Hematology;2024-07-27
2. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma;Advances in Therapy;2024-02-24
3. Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features;Nature Communications;2024-02-20
4. Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia;Blood Science;2024-01
5. The Involvement of LAG-3positive Plasma Cells in the Development of Multiple Myeloma;International Journal of Molecular Sciences;2023-12-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3